The US Food and Drug Administration approved Zhejiang Huahai Pharmaceutical (SHA:600521) subsidiary Shanghai Huaotai Biopharmaceutical's phase 1 trial application for its HB0043 injection, according to a Thursday filing with the Shanghai bourse.
The trial is for the indication of hidradenitis suppurativa, a condition that causes lumps to form under the skin.
The drug targets various difficult-to-treat autoimmune diseases, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments